Education
About Us
Working with TipRanks
Follow Us
Akari Therapeutics (AKTX)
NASDAQ:AKTX
AKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $4.22
Previous CloseN/A
Volume16.29K
Average Volume (3M)24.45K
Market Cap
$28.44M
Enterprise Value$21.25M
Total Cash (Recent Filing)$2.58M
Total Debt (Recent Filing)$1.85M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Sep 25, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding32,176,370
10 Day Avg. Volume32,982
30 Day Avg. Volume24,445
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$6.00Price Target Upside494.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Innovative ApproachAkari Therapeutics is using a novel payload approach in the high-value ADC space.
Stock RecommendationAnalyst recommendation is a Buy for Akari Therapeutics stock.
Bears Say
Partnership UncertaintyThe company is actively seeking partners to enhance its position.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $0.85 and its highest was $4.22 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $28.44M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is Sep 25, 2025 which is in 47 days.
How were Akari Therapeutics’s earnings last quarter?
Currently, no data Available
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 32,176,370 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
Akari Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (494.06% Upside)
$6.00 (494.06% Upside)
Insider Transactions
Bought Shares
Worth $37.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.74%
12-Months-Change
Fundamentals
Return on Equity
-197.11%
Trailing 12-Months
Asset Growth
1738.35%
Trailing 12-Months
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
AKTX Stock 12 Month Forecast
Average Price Target
$6.00
▲(494.06% Upside)
Technical Analysis
X4 Pharmaceuticals
―
Lantern Pharma
―
Shattuck Labs
―
Coeptis Therapeutics Holdings
―
LAVA Therapeutics
―
Ownership Overview
36.37% Insiders
0.76% Other Institutional Investors
62.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---